GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 203 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q2 2018. The put-call ratio across all filers is 0.35 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $508,000 | -64.7% | 15,906 | -61.7% | 0.01% | -61.5% |
| Q1 2022 | $1,440,000 | -47.4% | 41,579 | -55.5% | 0.01% | -48.0% |
| Q4 2021 | $2,738,000 | +112.7% | 93,540 | +85.3% | 0.02% | +92.3% |
| Q3 2021 | $1,287,000 | +88.4% | 50,473 | +158.8% | 0.01% | +85.7% |
| Q2 2021 | $683,000 | -67.0% | 19,500 | -59.2% | 0.01% | -75.0% |
| Q4 2020 | $2,068,000 | -69.5% | 47,739 | -62.9% | 0.03% | -88.3% |
| Q2 2019 | $6,770,000 | +75.3% | 128,700 | +76.3% | 0.24% | +78.4% |
| Q1 2019 | $3,863,000 | +792.1% | 73,000 | +540.4% | 0.13% | +605.3% |
| Q3 2018 | $433,000 | -87.6% | 11,400 | -85.3% | 0.02% | -90.0% |
| Q2 2018 | $3,503,000 | +298.1% | 77,500 | +246.8% | 0.19% | +163.9% |
| Q4 2017 | $880,000 | -61.1% | 22,350 | -69.3% | 0.07% | -65.2% |
| Q3 2017 | $2,264,000 | +75.1% | 72,891 | -6.4% | 0.21% | -28.4% |
| Q2 2016 | $1,293,000 | – | 77,912 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
| Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
| Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
| Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
| HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
| Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
| ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
| HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
| Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
| Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |